The neuroprotective treatment with induced hypothermia and xenon
The 2010 ILCOR guidelines for newborn resuscitation advised for the first time that term infants with moderate or severe perinatal asphyxia should be offered induced hypothermia treatment within 6h of life, i.e. being cooled for 72h to 33-34˚C body temperature. This was the first neuroprotective treatment proven to be effective in this population.
We have been developing the combined treatment of cooling and breathing the inert gas xenon in small and large animal models since 2003 and proved it to be effective. The combination of hypothermia and xenon doubles neuroprotection experimentally in rats and pigs.
Prof. Marianne Thoresen’s group in Bristol is currently running a clinical RCT adding breathing xenon for 18h to those undergoing standard cooling treatment (first in the world). In Oslo, we are working on preclinical studies in order to further develop xenon treatment, alone and in combination with hypothermia treatment.
Cardiac stroke volume and its contribution to the circulation: Interaction of mechanical and nervous factors affecting the heart
Cardiac output is one of the most important factors determining the circulatory state in both healthy subjects and patients. Cardiac output is determined by heart rate and stroke volume. Heart rate changes in healthy humans and patients are well characterized, while more knowledge is needed about stroke volume changes in humans.
This project will investigate the contribution of cardiac stroke volume to the circulation in healthy humans.
Skin circulation and temperature regulation
The blood flow to different areas of the human skin have been investigated as functions both of the core temperature, the environmental temperature and the local temperature applied to the skin. This project involves also the development of methods (fluctuating subatmospheric pressure) which can be applied to the skin to effectively cool a human under heat stress and warm a hypothermic person.